APO Research
Talk to an analyst

APO RESEARCH · REPORT

Liquid Embolic Agent

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Liquid Embolic Agent Market Outlook and Growth Opportunities 2026

4 July 2026194 pages

Choose your research edition.

Industry ResearchLiquid Embolic Agent Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Liquid Embolic Agent Industry Growth and Trends Forecast to 203296 pages · $3,450 USDMarket StructureGlobal Liquid Embolic Agent Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Liquid Embolic Agent Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Liquid Embolic Agent Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Liquid Embolic Agent market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Liquid Embolic Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Liquid Embolic Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Liquid Embolic Agent is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Liquid Embolic Agent market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Liquid Embolic Agent market include Saikesaisi Holding, Johnson & Johnson, Medtronic, Meril Life, BlackSwan Vascular and Balt Group, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Liquid Embolic Agent market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Liquid Embolic Agent and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Liquid Embolic Agent sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Liquid Embolic Agent market size, projected growth trends, production technologies, key applications, and end-use industries.

Liquid Embolic Agent Segment by Company

Saikesaisi Holding

Johnson & Johnson

Medtronic

Meril Life

BlackSwan Vascular

Balt Group

Liquid Embolic Agent Segment by Type

EVOH Type

nBCA Type

Other

Liquid Embolic Agent Segment by Application

Cerebral Arteriovenous Malformations (AVMs)

Dural Arteriovenous Fistulas (DAVFs)

Other

Liquid Embolic Agent Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Liquid Embolic Agent status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Liquid Embolic Agent market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Liquid Embolic Agent significant trends, drivers, influence factors in global and regions.

6. To analyze Liquid Embolic Agent competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liquid Embolic Agent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Liquid Embolic Agent and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liquid Embolic Agent.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Liquid Embolic Agent market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Liquid Embolic Agent industry.

Chapter 3: Detailed analysis of Liquid Embolic Agent manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Liquid Embolic Agent in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Liquid Embolic Agent in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Liquid Embolic Agent Industry Trends Table 2. Liquid Embolic Agent Industry Drivers Table 3. Liquid Embolic Agent Industry Opportunities and Challenges Table 4. Liquid Embolic Agent Industry Restraints Table 5. Global Liquid Embolic Agent Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Liquid Embolic Agent Revenue Share by Company (2021-2026) Table 7. Global Liquid Embolic Agent Sales Volume by Company (k units) & (2021-2026) Table 8. Global Liquid Embolic Agent Sales Volume Share by Company (2021-2026) Table 9. Global Liquid Embolic Agent Average Price (USD/unit) of Company (2021-2026) Table 10. Global Liquid Embolic Agent Company Ranking, (2024-2026) & (USD Million) Table 11. Global Liquid Embolic Agent Key Company Manufacturing Base & Headquarters Table 12. Global Liquid Embolic Agent Company, Product Type & Application Table 13. Global Liquid Embolic Agent Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Liquid Embolic Agent by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of EVOH Type Table 18. Significant Companies of nBCA Type Table 19. Significant Companies of Other Table 20. Global Liquid Embolic Agent Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global Liquid Embolic Agent Sales Volume by Type (2021-2026) & (k units) Table 22. Global Liquid Embolic Agent Sales Volume by Type (2027-2032) & (k units) Table 23. Global Liquid Embolic Agent Sales Volume Share by Type (2021-2026) Table 24. Global Liquid Embolic Agent Sales Volume Share by Type (2027-2032) Table 25. Global Liquid Embolic Agent Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Liquid Embolic Agent Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Liquid Embolic Agent Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Liquid Embolic Agent Sales Value Share by Type (2021-2026) Table 29. Global Liquid Embolic Agent Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Cerebral Arteriovenous Malformations (AVMs) Table 31. Significant Companies of Dural Arteriovenous Fistulas (DAVFs) Table 32. Significant Companies of Other Table 33. Global Liquid Embolic Agent Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Liquid Embolic Agent Sales Volume by Application (2021-2026) & (k units) Table 35. Global Liquid Embolic Agent Sales Volume by Application (2027-2032) & (k units) Table 36. Global Liquid Embolic Agent Sales Volume Share by Application (2021-2026) Table 37. Global Liquid Embolic Agent Sales Volume Share by Application (2027-2032) Table 38. Global Liquid Embolic Agent Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Liquid Embolic Agent Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Liquid Embolic Agent Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Liquid Embolic Agent Sales Value Share by Application (2021-2026) Table 42. Global Liquid Embolic Agent Sales Value Share by Application (2027-2032) Table 43. Global Liquid Embolic Agent Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Liquid Embolic Agent Sales by Region (2021-2026) & (k units) Table 45. Global Liquid Embolic Agent Sales Market Share by Region (2021-2026) Table 46. Global Liquid Embolic Agent Sales by Region (2027-2032) & (k units) Table 47. Global Liquid Embolic Agent Sales Market Share by Region (2027-2032) Table 48. Global Liquid Embolic Agent Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Liquid Embolic Agent Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Liquid Embolic Agent Sales Value Share by Region (2021-2026) Table 51. Global Liquid Embolic Agent Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Liquid Embolic Agent Sales Value Share by Region (2027-2032) Table 53. Global Liquid Embolic Agent Market Average Price (USD/unit) by Region (2021-2026) Table 54. Global Liquid Embolic Agent Market Average Price (USD/unit) by Region (2027-2032) Table 55. Global Liquid Embolic Agent Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Global Liquid Embolic Agent Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Liquid Embolic Agent Sales by Country (2021-2026) & (k units) Table 58. Global Liquid Embolic Agent Sales Market Share by Country (2021-2026) Table 59. Global Liquid Embolic Agent Sales by Country (2027-2032) & (k units) Table 60. Global Liquid Embolic Agent Sales Market Share by Country (2027-2032) Table 61. Global Liquid Embolic Agent Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Liquid Embolic Agent Sales Value Market Share by Country (2021-2026) Table 63. Global Liquid Embolic Agent Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Liquid Embolic Agent Sales Value Market Share by Country (2027-2032) Table 65. Saikesaisi Holding Company Information Table 66. Saikesaisi Holding Business Overview Table 67. Saikesaisi Holding Liquid Embolic Agent Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 68. Saikesaisi Holding Liquid Embolic Agent Product Portfolio Table 69. Saikesaisi Holding Recent Development Table 70. Johnson & Johnson Company Information Table 71. Johnson & Johnson Business Overview Table 72. Johnson & Johnson Liquid Embolic Agent Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 73. Johnson & Johnson Liquid Embolic Agent Product Portfolio Table 74. Johnson & Johnson Recent Development Table 75. Medtronic Company Information Table 76. Medtronic Business Overview Table 77. Medtronic Liquid Embolic Agent Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 78. Medtronic Liquid Embolic Agent Product Portfolio Table 79. Medtronic Recent Development Table 80. Meril Life Company Information Table 81. Meril Life Business Overview Table 82. Meril Life Liquid Embolic Agent Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 83. Meril Life Liquid Embolic Agent Product Portfolio Table 84. Meril Life Recent Development Table 85. BlackSwan Vascular Company Information Table 86. BlackSwan Vascular Business Overview Table 87. BlackSwan Vascular Liquid Embolic Agent Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 88. BlackSwan Vascular Liquid Embolic Agent Product Portfolio Table 89. BlackSwan Vascular Recent Development Table 90. Balt Group Company Information Table 91. Balt Group Business Overview Table 92. Balt Group Liquid Embolic Agent Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. Balt Group Liquid Embolic Agent Product Portfolio Table 94. Balt Group Recent Development Table 95. Key Raw Materials Table 96. Raw Materials Key Suppliers Table 97. Liquid Embolic Agent Distributors List Table 98. Liquid Embolic Agent Customers List Table 99. Research Programs/Design for This Report Table 100. Authors List of This Report Table 101. Secondary Sources Table 102. Primary Sources List of Figures Figure 1. Liquid Embolic Agent Product Image Figure 2. Global Liquid Embolic Agent Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Liquid Embolic Agent Sales Value (2021-2032) & (US$ Million) Figure 4. Global Liquid Embolic Agent Sales (2021-2032) & (k units) Figure 5. Global Liquid Embolic Agent Sales Average Price (USD/unit) & (2021-2032) Figure 6. Global Liquid Embolic Agent Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. EVOH Type Image Figure 10. nBCA Type Image Figure 11. Other Image Figure 12. Global Liquid Embolic Agent Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global Liquid Embolic Agent Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Liquid Embolic Agent Sales Volume Share by Type (2021-2032) Figure 15. Global Liquid Embolic Agent Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Liquid Embolic Agent Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Liquid Embolic Agent Sales Value Share by Type (2021-2032) Figure 18. Cerebral Arteriovenous Malformations (AVMs) Image Figure 19. Dural Arteriovenous Fistulas (DAVFs) Image Figure 20. Other Image Figure 21. Global Liquid Embolic Agent Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Liquid Embolic Agent Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Liquid Embolic Agent Sales Volume Share by Application (2021-2032) Figure 24. Global Liquid Embolic Agent Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Liquid Embolic Agent Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Liquid Embolic Agent Sales Value Share by Application (2021-2032) Figure 27. Global Liquid Embolic Agent Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 28. Global Liquid Embolic Agent Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Liquid Embolic Agent Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Liquid Embolic Agent Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Liquid Embolic Agent Sales Value (2021-2032) & (US$ Million) Figure 32. North America Liquid Embolic Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Liquid Embolic Agent Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Liquid Embolic Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Liquid Embolic Agent Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Liquid Embolic Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Liquid Embolic Agent Sales Value (2021-2032) & (US$ Million) Figure 38. South America Liquid Embolic Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Liquid Embolic Agent Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Liquid Embolic Agent Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Liquid Embolic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Liquid Embolic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Liquid Embolic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Liquid Embolic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Liquid Embolic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Liquid Embolic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Liquid Embolic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Liquid Embolic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Liquid Embolic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Liquid Embolic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Liquid Embolic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Liquid Embolic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Liquid Embolic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Liquid Embolic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Liquid Embolic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Liquid Embolic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Liquid Embolic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Liquid Embolic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Liquid Embolic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Liquid Embolic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Liquid Embolic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Liquid Embolic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Liquid Embolic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Liquid Embolic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Liquid Embolic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Liquid Embolic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Liquid Embolic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Liquid Embolic Agent Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Liquid Embolic Agent Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Liquid Embolic Agent Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • EVOH Type
  • nBCA Type
  • Other
Applications
  • Cerebral Arteriovenous Malformations (AVMs)
  • Dural Arteriovenous Fistulas (DAVFs)
  • Other
Companies covered
  • Saikesaisi Holding
  • Johnson & Johnson
  • Medtronic
  • Meril Life
  • BlackSwan Vascular
  • Balt Group

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Liquid Embolic Agent Sales Value (2021-2032)
  4. 1.2.2 Global Liquid Embolic Agent Sales Volume (2021-2032)
  5. 1.2.3 Global Liquid Embolic Agent Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Liquid Embolic Agent Market Dynamics
  1. 2.1 Liquid Embolic Agent Industry Trends
  2. 2.2 Liquid Embolic Agent Industry Drivers
  3. 2.3 Liquid Embolic Agent Industry Opportunities and Challenges
  4. 2.4 Liquid Embolic Agent Industry Restraints
3 Liquid Embolic Agent Market by Company
  1. 3.1 Global Liquid Embolic Agent Company Revenue Ranking in 2025
  2. 3.2 Global Liquid Embolic Agent Revenue by Company (2021-2026)
  3. 3.3 Global Liquid Embolic Agent Sales Volume by Company (2021-2026)
  4. 3.4 Global Liquid Embolic Agent Average Price by Company (2021-2026)
  5. 3.5 Global Liquid Embolic Agent Company Ranking (2024-2026)
  6. 3.6 Global Liquid Embolic Agent Company Manufacturing Base and Headquarters
  7. 3.7 Global Liquid Embolic Agent Company Product Type and Application
  8. 3.8 Global Liquid Embolic Agent Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Liquid Embolic Agent Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Liquid Embolic Agent Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Liquid Embolic Agent Market by Type
  1. 4.1 Liquid Embolic Agent Type Introduction
  2. 4.1.1 EVOH Type
  3. 4.1.2 nBCA Type
  4. 4.1.3 Other
  5. 4.2 Global Liquid Embolic Agent Sales Volume by Type
  6. 4.2.1 Global Liquid Embolic Agent Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Liquid Embolic Agent Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Liquid Embolic Agent Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Liquid Embolic Agent Sales Value by Type
  10. 4.3.1 Global Liquid Embolic Agent Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Liquid Embolic Agent Sales Value by Type (2021-2032)
  12. 4.3.3 Global Liquid Embolic Agent Sales Value Share by Type (2021-2032)
5 Liquid Embolic Agent Market by Application
  1. 5.1 Liquid Embolic Agent Application Introduction
  2. 5.1.1 Cerebral Arteriovenous Malformations (AVMs)
  3. 5.1.2 Dural Arteriovenous Fistulas (DAVFs)
  4. 5.1.3 Other
  5. 5.2 Global Liquid Embolic Agent Sales Volume by Application
  6. 5.2.1 Global Liquid Embolic Agent Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Liquid Embolic Agent Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Liquid Embolic Agent Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Liquid Embolic Agent Sales Value by Application
  10. 5.3.1 Global Liquid Embolic Agent Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Liquid Embolic Agent Sales Value by Application (2021-2032)
  12. 5.3.3 Global Liquid Embolic Agent Sales Value Share by Application (2021-2032)
6 Liquid Embolic Agent Regional Sales and Value Analysis
  1. 6.1 Global Liquid Embolic Agent Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Liquid Embolic Agent Sales by Region (2021-2032)
  3. 6.2.1 Global Liquid Embolic Agent Sales by Region: 2021-2026
  4. 6.2.2 Global Liquid Embolic Agent Sales by Region (2027-2032)
  5. 6.3 Global Liquid Embolic Agent Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Liquid Embolic Agent Sales Value by Region (2021-2032)
  7. 6.4.1 Global Liquid Embolic Agent Sales Value by Region: 2021-2026
  8. 6.4.2 Global Liquid Embolic Agent Sales Value by Region (2027-2032)
  9. 6.5 Global Liquid Embolic Agent Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Liquid Embolic Agent Sales Value (2021-2032)
  12. 6.6.2 North America Liquid Embolic Agent Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Liquid Embolic Agent Sales Value (2021-2032)
  15. 6.7.2 Europe Liquid Embolic Agent Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Liquid Embolic Agent Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Liquid Embolic Agent Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Liquid Embolic Agent Sales Value (2021-2032)
  21. 6.9.2 South America Liquid Embolic Agent Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Liquid Embolic Agent Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Liquid Embolic Agent Sales Value Share by Country, 2025 VS 2032
7 Liquid Embolic Agent Country-level Sales and Value Analysis
  1. 7.1 Global Liquid Embolic Agent Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Liquid Embolic Agent Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Liquid Embolic Agent Sales by Country (2021-2032)
  4. 7.3.1 Global Liquid Embolic Agent Sales by Country (2021-2026)
  5. 7.3.2 Global Liquid Embolic Agent Sales by Country (2027-2032)
  6. 7.4 Global Liquid Embolic Agent Sales Value by Country (2021-2032)
  7. 7.4.1 Global Liquid Embolic Agent Sales Value by Country (2021-2026)
  8. 7.4.2 Global Liquid Embolic Agent Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Liquid Embolic Agent Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Liquid Embolic Agent Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Liquid Embolic Agent Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Liquid Embolic Agent Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Liquid Embolic Agent Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Liquid Embolic Agent Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Liquid Embolic Agent Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Liquid Embolic Agent Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Liquid Embolic Agent Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Liquid Embolic Agent Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Liquid Embolic Agent Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Liquid Embolic Agent Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Liquid Embolic Agent Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Liquid Embolic Agent Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Liquid Embolic Agent Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Liquid Embolic Agent Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Liquid Embolic Agent Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Liquid Embolic Agent Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Liquid Embolic Agent Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Liquid Embolic Agent Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Liquid Embolic Agent Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Liquid Embolic Agent Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Liquid Embolic Agent Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Liquid Embolic Agent Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Liquid Embolic Agent Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Liquid Embolic Agent Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Liquid Embolic Agent Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Liquid Embolic Agent Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Liquid Embolic Agent Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Liquid Embolic Agent Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Saikesaisi Holding
  2. 8.1.1 Saikesaisi Holding Company Information
  3. 8.1.2 Saikesaisi Holding Business Overview
  4. 8.1.3 Saikesaisi Holding Liquid Embolic Agent Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Saikesaisi Holding Liquid Embolic Agent Product Portfolio
  6. 8.1.5 Saikesaisi Holding Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Liquid Embolic Agent Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Liquid Embolic Agent Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Medtronic
  14. 8.3.1 Medtronic Company Information
  15. 8.3.2 Medtronic Business Overview
  16. 8.3.3 Medtronic Liquid Embolic Agent Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Medtronic Liquid Embolic Agent Product Portfolio
  18. 8.3.5 Medtronic Recent Developments
  19. 8.4 Meril Life
  20. 8.4.1 Meril Life Company Information
  21. 8.4.2 Meril Life Business Overview
  22. 8.4.3 Meril Life Liquid Embolic Agent Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Meril Life Liquid Embolic Agent Product Portfolio
  24. 8.4.5 Meril Life Recent Developments
  25. 8.5 BlackSwan Vascular
  26. 8.5.1 BlackSwan Vascular Company Information
  27. 8.5.2 BlackSwan Vascular Business Overview
  28. 8.5.3 BlackSwan Vascular Liquid Embolic Agent Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 BlackSwan Vascular Liquid Embolic Agent Product Portfolio
  30. 8.5.5 BlackSwan Vascular Recent Developments
  31. 8.6 Balt Group
  32. 8.6.1 Balt Group Company Information
  33. 8.6.2 Balt Group Business Overview
  34. 8.6.3 Balt Group Liquid Embolic Agent Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Balt Group Liquid Embolic Agent Product Portfolio
  36. 8.6.5 Balt Group Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Liquid Embolic Agent Value Chain Analysis
  2. 9.1.1 Liquid Embolic Agent Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Liquid Embolic Agent Sales Mode & Process
  6. 9.2 Liquid Embolic Agent Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Liquid Embolic Agent Distributors
  9. 9.2.3 Liquid Embolic Agent Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst